Question brief
Ask for names, records, and a complete plan.
A legitimate care option can identify the doctor or other health professional, the pharmacy, the exact product, the full price, and what happens next.
The care check
Start with the people and place behind the screen
- What is the doctor’s or other health professional’s full name and licence type?
- Are they licensed, or otherwise legally permitted, to provide care in the state where the patient will be?
- Which pharmacy makes or sends the medicine?
- Is that pharmacy licensed by the patient’s state board of pharmacy?
- Can that person ask follow-up questions instead of relying on a fixed form?
Every state has a medical board with public licence and discipline records. Pharmacy licences are kept by a separate state board of pharmacy.
Check three records
Health professional
State licence
Pharmacy
The product check
“Liraglutide” is not a complete answer
Ask whether the prescription is for Victoza-type or Saxenda-type liraglutide, and whether it is a brand, an FDA-approved generic, or a made-to-order medicine called a compounded preparation.
As of September 26, 2026, FDA-approved generic liraglutide existed for both diabetes and weight management.
A compounded medicine is not FDA-approved. Before a compounded medicine is sold, the FDA does not confirm that it works, is safe, or was made well.
The diabetes versions and weight-management versions carry different approved uses and are not swapped for each other at the pharmacy.
Name the product type
Brand
Generic
Compounded
These words do not mean the same thing.
Compounding status
What the shortage means—and does not mean
As of September 26, 2026, liraglutide injection remained on the FDA drug shortage list. Some versions had limited supply, while several generic versions were listed as available; ask the pharmacy about the exact product on the prescription.
While a medicine is officially in short supply, a compounder may be allowed to make a version of it.
Separately, on May 1, 2026, the FDA proposed keeping liraglutide off a list of ingredients that larger facilities may use because of a clinical need. The proposal was not final as of September 26, 2026.
The shortage listing alone does not prove that a particular compounded offer is legal. Ask whether the product is FDA-approved. If it is not, ask who made it and why a made-to-order version is being used. Check an ordinary pharmacy with the state board of pharmacy; check a larger registered facility on the FDA’s outsourcing-facility list.
What an online visit can involve
Remote care still needs a real assessment
A service may verify identity and location, collect health information, let a doctor or other health professional review it, ask follow-up questions, and explain the care plan.
A fixed tick-box form on its own is not enough when nobody can ask a follow-up question.
A first appointment does not always require live video. An interactive form can sometimes be used if the doctor or other health professional can gather the needed information and ask follow-up questions. State rules differ, so ask the state medical board what applies where the patient will be during the visit.
A care flow
Information → doctor review → follow-up questions → care plan
Bring these questions
Cover the reason, cost, and follow-up
Which version is this?
Is it the diabetes version or the weight-management version? What exact name will appear on the prescription?
Why this product?
What is the intended use, and what other options were considered?
What is the whole cost?
Which visit, medicine, lab, supply, shipping, and follow-up charges are included?
What will be checked?
Which health history and lab work will be reviewed, and what signs will show whether treatment is helping?
Who answers a problem?
How can a patient reach the care team, and what happens outside a planned visit?
What is the longer plan?
What happens if the medicine is not helping, is not covered, or is no longer available?
A dated supply question
Ask what follows the Saxenda brand
The maker says the last Saxenda shipments to wholesalers will be in late January 2027. The stated reason is a business decision, not a safety or quality problem.
As of September 26, 2026, other FDA-approved Saxenda-type generics existed, but approval does not guarantee that a product is stocked at a particular pharmacy.
A practical question
What comes next?
Page footnotes